Business Context and Reporting Period
Company: Indivior PLC (trading as Indivior Pharmaceuticals, Inc. in the request metadata)
Filing Type: Form 8-K (Current Report)
Date of Report: November 20, 2025
Event: Termination of a Material Agreement (Resolution Agreement with the U.S. Department of Justice).
Key Financial Metrics
This filing does not contain specific financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The report focuses exclusively on the legal resolution of a prior agreement.
Material Changes
- Termination of Resolution Agreement: On November 20, 2025, the Company satisfied all remaining obligations under the Resolution Agreement dated July 24, 2020, involving Indivior Inc., Indivior PLC, the U.S. Attorney's Office for the Western District of Virginia, and the DOJ's Consumer Protection Branch.
- Agreement Status: The Resolution Agreement officially terminated on November 20, 2025.
- Payment Completion: The Company announced the payment of all remaining amounts owed to the DOJ.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the conclusion of the legal matter and the fulfillment of financial obligations to the DOJ. No forward-looking guidance or outlook is provided in this specific document.
Risks and Contingencies: The termination of the Resolution Agreement removes the specific contingencies and obligations associated with that 2020 agreement. The filing does not disclose new material risks.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for details on the final payment amount.
- Confirm the removal of any ongoing compliance monitoring requirements previously stipulated in the 2020 Resolution Agreement.
- Review subsequent filings for any impact on the Company's balance sheet or cash flow resulting from the final settlement payment.